Allergan Inc. is taking the wraps off of Juv & #269;derm, its wrinkle reducing drug that it acquired through its $3.2 billion buy of Inamed Corp.
The Irvine drug maker on Tuesday said it was introducing Juv & #269;derm through an “experience trial” involving cosmetic surgery doctors.
Allergan plans a nationwide launch in January, and accepting pre-orders for the product on Nov. 1.
The drug maker is looking to Juv & #269;derm’s scientific benefits to establish the product alongside flagship Botox.
The two products are being called a “total facial rejuvenation offering,” said Robert Grant, an Allergan corporate vice president and Inamed president, in a statement.
Juv & #269;derm, which was cleared by the Food and Drug Administration in June, comes in two forms, with one targeting deeper wrinkles.
